Aceso Therapeutics

Aceso Therapeutics is a biotech company leveraging years of academic research and collaborative innovation to build a scalable platform addressing major unmet medical needs. Our portfolio includes three patented first-in-class molecules, with a primary focus on respiratory diseases. Our most advanced program is a bitherapy for cystic fibrosis, designed to overcome the limitations of current treatments. Backed by robust preclinical data and advanced development work, this program is now moving toward IND-enabling studies, with clinical entry as the next major milestone. Founded by Thomas Tran (CEO) and the scientists and inventors of the patented molecules, Aceso is powered by a committed and complementary team, supported by a strong biotech ecosystem in Occitanie, France. At Aceso, we believe that our dual-target approach can redefine standards of care where existing therapies fall short. With a science-driven roadmap and a strong IP position, we are well-positioned to accelerate pipeline development and deliver meaningful therapeutic breakthroughs. -> Learn more at www.aceso-therapeutics.com or contact us : contact@aceso-therapeutics.com.